Finally, although further studies are needed to fully understand the role of this receptor in different pneumonia models, to our knowledge, the present study provides the first preclinical proof of concept that PAR-1 antagonism may represent a potential novel therapeutic approach for the prevention of excessive neutrophilic lung injury associated with bacterial pneumonia. This evidence concerns the gene F2R and susceptibility to pneumonia measurement.